Research on the Application of 99mTc-TCR-FAPI SPECT Imaging in Rheumatoid Arthritis
Recruiting · NCT07138729 · Interventional (participants receive a specific treatment) · Lead sponsor: Luo Yaping
View the official record on ClinicalTrials.gov →Interventions studied
68Ga-FAPI PET/CT and 99mTc-CTR-FAPI SPECT
What this trial is about
This study proposes to evaluate 99mTc-CTR-FAPI SPECT imaging as a cost-effective, low-radiation, and widely accessible alternative to 68Ga-FAPI PET/CT for assessing synovial lesions in RA patients, aiming to validate its diagnostic consistency with both PET/CT and physical examinations while correlating imaging findings with clinical disease activity metrics to establish a practical tool for long-term RA monitoring.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age: 18-75 years old;
- Meet the classification criteria for rheumatoid arthritis of the American College of Rheumatology/European Union for Rheumatology in 2010;
- The highest disease activity in clinical practice (CDAI or SDAI score
Exclusion criteria
- Patients with other autoimmune diseases;
- Patients with concurrent tumors;
- Women who are pregnant or planning to become pregnant, women in the preconception period, pregnant and lactating women, and women with child-rearing plans during the study period; Subjects of childbearing age need to take effective contraceptive measures during the research process;
- Active infection
- Suffering from claustrophobia or other mental disorders, with poor compliance resulting in inability to cooperate with this researcher; (6) Situations where other researchers consider it inappropriate to participate in this clinical trial.
Where it is running
1 location listed.
- Peking Union Medical College Hospital - Beijing, Beijing Municipality, China